Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
Lorenc R, Shouval R, Flynn JR, Devlin SM, Saldia A, De Abia AL, De Lapuerta MC, Tomas AA, Cassanello G, Leslie LA, Rejeski K, Lin RJ, Scordo M, Shah GL, Palomba ML, Salles G, Park J, Giralt SA, Perales MA, Ip A, Dahi PB. Lorenc R, et al. Among authors: ip a. Transplant Cell Ther. 2024 Oct;30(10):990-1000. doi: 10.1016/j.jtct.2024.06.027. Epub 2024 Jul 6. Transplant Cell Ther. 2024. PMID: 38972512
[No title available]
[No authors listed] [No authors listed] PMID: 38580234
Cancer survivor preferences on the timing and content of interventions to mitigate financial toxicity associated with cancer treatment.
Huq MR, Schwartz MD, Derry-Vick H, Khoudary A, Sorgen L, Billini O, Gunning TS, Luck C, Kaushik S, Hurley VB, Marshall J, Weinberg BA, Tesfaye A, Ip A, Potosky AL, Conley CC. Huq MR, et al. Among authors: ip a. Support Care Cancer. 2024 Nov 8;32(12):778. doi: 10.1007/s00520-024-08983-5. Support Care Cancer. 2024. PMID: 39511025
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
Danish A, Della Pia A, Fogel L, Alkhatatneh H, Zhao C, Varughese T, Al Feghali KA, Pascual L, Sinclaire B, Marafelias M, Zenreich J, Kuo YH, Feldman TA, Zhang Y, Goy AH, Ip A, Rowley SD. Danish A, et al. Among authors: ip a. Front Oncol. 2024 Aug 19;14:1425506. doi: 10.3389/fonc.2024.1425506. eCollection 2024. Front Oncol. 2024. PMID: 39228984 Free PMC article.
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
Rosenthal A, Munoz J, Jun M, Wang T, Mutebi A, Wang A, Yang S, Osei-Bonsu K, Elliott B, Rivas Navarro F, Yu J, Brodkin S, Sacchi M, Ip A. Rosenthal A, et al. Among authors: ip a. J Hematol Oncol. 2024 Aug 16;17(1):69. doi: 10.1186/s13045-024-01594-x. J Hematol Oncol. 2024. PMID: 39152509 Free PMC article.
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.
Shah NJ, Della Pia A, Wu T, Williams A, Weber M, Sinclaire B, Gourna Paleoudis E, Alaoui A, Lev-Ari S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan M, Cheruku D, Lee A, Sridhar A, Hee BTP, Ahn J, Pecora A, Ip A, Atkins MB. Shah NJ, et al. Among authors: ip a. Cancers (Basel). 2024 Jun 14;16(12):2223. doi: 10.3390/cancers16122223. Cancers (Basel). 2024. PMID: 38927928 Free PMC article.
188 results